ZIMMERMANN HOLGER
No ORCID on file
· 54 papers in corpus
· active 2008-2012
Frequent coauthors
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2012
Disclosed is the use of 17alpha-Cyanomethyl-17-beta-hydroxyestra-4,9-diene-3-one (Dienogest) for the manufacture of a pharmaceutical product for monophasic continuous administration of 2 mg Dienogest daily for at least 169 days or 25 weeks …
2011
The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that requi…
2011
The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that requi…
2011
The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that requi…
2010
Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…
2010
Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…
2010
Antiandrogenic gestagens in a daily dosage unit, corresponding to no more than two times the dosage required to suppress ovulation, are used in combination with (6S)-5-methyltetrahydrofolate for the production of pharmaceutical preparations…
2010
2010
2010
2010
2010
2010
2009
2009
2009
2009
2009
2009
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17Î+--cyanomethyl-17Ã -hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacet…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17Î+--cyanomethyl-17Ã -hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacet…
2009
A pharmaceutical composition for the treatment of endometriosis without loss of bone density comprises a gestagenic having an antiandrogenic effect, preferably 17Î+--cyanomethyl-17Ã -hydroxy-estra-4,9-diene-3-one (Dienogest), cyproteronacet…
2009
A combination of an anti-androgenic gestagen at a daily dose of from an ovulation-inhibiting dose up to at most twice the ovulation-inhibiting dose and from 0.1 to 10 mg of (6S)-5-methyltetrahydrofolate are used to produce a pharmaceutical …